Humulin — Competitive Intelligence Brief

Humulin (insulin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin Analog [EPC]. Area: Metabolic.

marketed Insulin Analog [EPC] Tyrosine-protein kinase Lck Metabolic

Target snapshot

Humulin (insulin) — Eli Lilly. Humulin works by binding to insulin receptors on cells, triggering a cascade of signals that lower blood glucose levels.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Humulin TARGET	insulin	Eli Lilly	marketed	Insulin Analog [EPC]	Tyrosine-protein kinase Lck	1982-01-01
Hydrocortisone And Acetic Acid	ACETIC ACID	Hikma	marketed	acetic acid	Tyrosine-protein kinase Lck	1960-01-01
Cortisporin	BACITRACIN	Pfizer	marketed	bacitracin	Tyrosine-protein kinase Lck	1948-01-01
ACETIC ACID	ACETIC ACID, GLACIAL	CHARTWELL RX	marketed		Free fatty acid receptor 3, Tyrosine-protein kinase Fyn, Tyrosine-protein kinase Lck
Adlyxin	LIXISENATIDE	Sanofi-Aventis Us Llc	marketed	Insulin Analog [EPC]	Glucagon-like peptide 1 receptor	2016-01-01
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin Analog [EPC] class)

1. Novo Nordisk · 3 drugs in this class
2. Eli Lilly · 2 drugs in this class
3. Sanofi · 2 drugs in this class
4. Emory University · 1 drug in this class
5. Sanofi-Aventis Us Llc · 1 drug in this class